GuillermoGarcia-ManeroMD

Oncology • Houston, TX

Hematologic Oncology

Professor, Hematology, University of Texas Medical School at Houston

Join to view full profile

Dr. Garcia-Manero is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Garcia-Manero's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 1996 - 1999
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 1993 - 1996
Universidad de Zaragoza Faculty of MedicineClass of 1991

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2000 - 2026
WA State Medical License 2024 - 2026
AZ State Medical License 2024 - 2025
GA State Medical License 2024 - 2025
LA State Medical License 2024 - 2025
MS State Medical License 2024 - 2025
OK State Medical License 2020 - 2025
TN State Medical License 2024 - 2025
AL State Medical License 2024 - 2024
PA State Medical License 1994 - 2014
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2014
America's Top Doctors for Cancer Castle Connolly, 2013
Super Doctor SuperDoctors.com

Clinical Trials

Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes Start of enrollment: 2004 Jan 23
Completed
Phase 1, Phase 2
Phase II 5-Azacytidine Plus VPA Plus ATRA Start of enrollment: 2005 Jul 01
Completed
Phase 2
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes Start of enrollment: 2006 Mar 01
Completed
Phase 1
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) Start of enrollment: 2006 Jul 01
Completed
Phase 1
Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients Start of enrollment: 2005 Aug 01
Completed
Phase 2
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Start of enrollment: 2008 Apr 01
Completed
Phase 2
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine Start of enrollment: 2007 Apr 01
Completed
Phase 1
PR1 Vaccination in Myelodysplastic Syndrome (MDS) Start of enrollment: 2006 Jul 01
Terminated
Phase 2
Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS) Start of enrollment: 2010 Jan 01
Completed
Phase 2
Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2009 Aug 01
Terminated
Phase 2
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study Start of enrollment: 2010 Mar 22
Completed
Phase 2
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2009 Sep 08
Completed
Phase 2
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) Start of enrollment: 2009 Dec 01
Completed
Phase 1, Phase 2
Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome Start of enrollment: 2011 May 01
Completed
Phase 1
SB1518 for Patients With Myelodysplastic Syndrome (MDS) Start of enrollment: 2011 Dec 01
Terminated
Phase 2
Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2011 Nov 16
Completed
Phase 2
Phase I Study of the Combination of 5-azacytidine With Valproic Acid and All-trans Retinoic Acid in Patients With High Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia Start of enrollment: 2005 Jul 01
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Start of enrollment: 2012 Sep 01
Completed
Phase 1
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome Start of enrollment: 2013 Jun 01
Completed
Phase 2
Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation Start of enrollment: 2013 Aug 07
Completed
Phase 2
Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Feb 01
Completed
Phase 1
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Start of enrollment: 2013 Dec 24
Completed
Phase 2
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine Start of enrollment: 2013 Aug 01
Completed
Phase 1, Phase 2
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Start of enrollment: 2013 Aug 01
Completed
Phase 3
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
Completed
Phase 2
Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes Start of enrollment: 2014 Nov 10
Active, not recruiting
Phase 2
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. Start of enrollment: 2014 Sep 11
Terminated
Phase 2
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies Start of enrollment: 2014 Jul 01
Completed
Phase 1, Phase 2
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA Start of enrollment: 2015 Dec 02
Terminated
Phase 3
Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 2017 Nov 06
Active, not recruiting
Phase 2
A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes Start of enrollment: 2017 Jun 01
Terminated
Phase 2
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia Start of enrollment: 2017 Jun 23
Terminated
Phase 3
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Start of enrollment: 2020 Aug 25
Recruiting
Phase 2
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS Start of enrollment: 2020 Jul 06
Recruiting
Phase 1, Phase 2
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Start of enrollment: 2020 Sep 04
Recruiting
Phase 1, Phase 2
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 2015 Sep 08
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Start of enrollment: 2021 Jan 19
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome Start of enrollment: 2019 Oct 01
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications Start of enrollment: 2016 Jan 01
Active, not recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) Start of enrollment: 2022 Dec 01
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms.
Jayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, Guillin Tang, Tapan Kadia
Haematologica. 2024-12-12
2 citations
Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations.
Fernanda Gutierrez-Rodrigues, Emma M Groarke, Natthakan Thongon, Juan Jose Rodriguez-Sevilla, Luiz Fernando B Catto
Blood. 2024-12-05
1 citations
A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.
Kelly S Chien, Juan Jose Rodriguez-Sevilla, Yesid Alvarado, Guillermo Montalban-Bravo, Danielle E Hammond
Leukemia Research. 2024-12-01

Abstracts/Posters

Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pt...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Gr...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) ...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration t...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphob...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA ...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphob...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidin...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Di...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with ...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Hematologic Improvement_Neutrophil and _Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspate...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidin...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A phase I study of AMV564 in patients with intermediate or high-risk myelodysplastic syndromes.
2019 ASCO Annual Meeting - 6/1/2019
Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Ta...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Telomere Damage Maintains Hematopoietic Stem Cells (HSCs) in an Activated Metabolic State, Which Compromises Their Self-Renewal Capability
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Diverse Landscape of TET2 Variants in MDS and AML
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Imapct of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Induced PD-1 Expression on Bone Marrow CD34+ Cells from MDS Patients Treated with 5-Azacitadine in Combination with Nivolumab and/or Ipilimumab
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant M...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leu...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic Syndromes (MDS):...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Authored Content

A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017
Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid MalignanciesOctober 2017
The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017
Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 Days (SGI5), 10 Days (SGI10), 5 Days + Idarubicin (SGI5 + Ida), and 5 Days + Cladribine (SGI5 + Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)–a Bayesian DesignOctober 2017
Join now to see all

Press Mentions

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and ExpositionDecember 9th, 2024
Taiho Oncology Data at ASH Annual Meeting Highlight Progress in Oral Therapies for Patients with Blood CancersDecember 9th, 2024
Researchers Discover an Origin of Idiopathic AutismDecember 4th, 2024
Join now to see all